Investment Thesis
Chemomab is a pre-revenue pharmaceutical company with significant cash burn and negative profitability, but maintains a strong balance sheet with $20.8M cash providing runway. The company is at a critical inflection point where clinical development progress and regulatory milestones will determine viability, presenting high execution risk typical of early-stage biotech.
Strengths
- Strong cash position of $20.8M with minimal debt provides runway for clinical development
- Excellent liquidity with 4.83x current ratio indicating ability to meet short-term obligations
- Zero debt/equity ratio eliminates refinancing and solvency risks
Risks
- Pre-revenue status with no commercial product generating income, entirely dependent on funding and cash reserves
- Severe cash burn of -$7.2M in operating cash flow demonstrates unsustainable burn rate relative to cash reserves
- Negative ROE of -31.3% and ROA of -25.0% indicate shareholder value destruction and asset inefficiency
- No revenue generation capability visible in current financial metrics creates existential business model risk
- Minimal insider trading activity (0 Form 4 filings in 90 days) suggests limited management confidence or activity
Key Metrics to Watch
- Quarterly operating cash burn rate and runway estimate based on current cash reserves
- Clinical trial progression, regulatory milestones, and FDA/EMA pathway updates
- Future financing activities and dilution impact from capital raises
Financial Metrics
Revenue
N/A
Net Income
-8.8M
EPS (Diluted)
$0.04
Free Cash Flow
-7.2M
Total Assets
35.0M
Cash
20.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-31.3%
ROA
-25.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.83x
Quick Ratio
4.83x
Debt/Equity
0.00x
Debt/Assets
20.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T14:02:10.382029 |
Data as of: 2023-03-31 |
Powered by Claude AI